Patients Could Still Be on the Hook for Outpatient Costs, Costs If They Test Negative, and Cost Sharing A new KFF analysis estimates that between 670,000 and 2 million uninsured people around the country eventually could be hospitalized with COVID-19, the respiratory disease caused by the novel coronavirus. Reimbursing hospitals…
- view as grid
- view as list
This brief estimates the total amount that will be spent to reimburse hospitals for care for the uninsured with COVID-19, the disease caused by the coronavirus.
There is ongoing discussion as to whether Congress should waive COVID-19 treatment costs. To inform these discussions, this analysis examines the extent of health care cost-related problems among Medicare beneficiaries. The analysis is based on a composite measure that includes problems getting care due to cost, delays seeking care due to cost, and problems paying medical bills among people with Medicare.
Medicare Part D plan sponsors, which provide drug coverage to 45 million older adults and people with disabilities, have the option to relax their ‘refill too soon’ restrictions in response to the COVID-19 pandemic, as part of efforts to ensure adequate access to medications in disasters or emergencies. This analysis examines the share of Part D enrollees who currently have access to extended supplies of generic, brand-name, and specialty-tier drugs covered by their plan in 2020, prior to relaxation of any early-fill restrictions in response to the COVID-19 outbreak.
These FAQs provide the latest guidance on testing and treatment related to COVID-19 for Medicare beneficiaries.
As the coronavirus continues to spread, the number of people on Medicare admitted to the hospital for COVID-19 related illness is expected to rise. We analyze how much Medicare beneficiaries could pay out-of-pocket for an inpatient hospital admission under traditional Medicare (assuming no supplemental coverage) or Medicare Advantage plans.
A summary of key provisions of the Families First Coronavirus Response Act that addresses the domestic coronavirus outbreak, including paid sick leave, insurance coverage of coronavirus testing, nutrition assistance, and unemployment benefits.
These FAQs provide background on prescription drug importation, including how the U.S. currently regulates importation and why it hasn’t been successfully implemented before. These FAQs also describe the newest importation proposals, both by the Trump Administration and at the state level, how these proposals seek to address concerns with prior proposals, and how stakeholders are viewing these newest proposals